Top

Published in:

01-07-2014 | Letter to the Editor

Rivaroxaban use following bariatric surgery

Authors: Zachariah Thomas, Yaron Bareket, Wendy Bennett

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2014

Excerpt

The recent case report by Dr. Mahlmann et al. [1] describing the pharmacokinetics of rivaroxaban in a bariatric surgery patient is a welcome addition to the literature. However, we feel it necessary to clarify the statement made regarding the “high bioavailability” of rivaroxaban and express caution regarding the use of this agent in postoperative bariatric surgery patients. …

Mahlmann A, Gehrisch S, Beyer-Westendorf J (2013) Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. J Thromb Thrombolysis 36:533–535PubMedCrossRef

Stampfuss J, Kubitza D, Becka M, Mueck W (2013) The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 51:549–561PubMedCrossRef

Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2006) Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46:549–558PubMedCrossRef

Xarelto Prescribing Information (2013). http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf. Accessed 17 Dec 2013

Protocol for: Patel MR, Mahaffey KW, Garg J, et al. (2013) Rivaroxaban versus warfarin in nonvalvular atrial abrillation. N Engl J Med 2011; http://www.nejm.org/doi/suppl/10.1056/NEJMoa1009638/suppl_file/nejmoa1009638_protocol.pdf. Accessed 17 Dec 2013

Protocol for: The EINSTEIN–PE investigators (2013). Oral rivaroxaban for the treatment of symptomatic pulmonary. N Engl J Med 2012; http://www.nejm.org/doi/suppl/10.1056/NEJMoa1113572/suppl_file/nejmoa1113572_protocol.pdf. Accessed 17 Dec 2013

Protocol for: The EINSTEIN investigators (2013). Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; http://www.nejm.org/doi/suppl/10.1056/NEJMoa1007903/suppl_file/nejmoa1007903_protocol.pdf. Accessed 17 Dec 2013

Centers for Disease Control and Prevention (2013). National Health and Nutrition Examination Survey. Intake of calories and selected nutrients for the United States Population, 1999–2000. http://www.cdc.gov/nchs/data/nhanes/databriefs/calories.pdf. Accessed 17 Dec 2013

Finks JF, English WJ, Carlin AM, Krause KR, Share DA, Banerjee M, Birkmeyer JD, Birkmeyer NJ (2012) Predicting risk for venous thromboembolism with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative. Ann Surg 255:1100–1104PubMedCrossRef

10.

Magnani JW, Hylek EM, Apovian CM (2013) Obesity begets atrial fibrillation: a contemporary summary. Circulation 128:401–405PubMedCrossRef

11.

Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59–7939) in healthy subjects. J Clin Pharmacol 47:218–226PubMedCrossRef

12.

University of California San Francisco (2013). Dietary guidelines after bariatric surgery. http://www.ucsfhealth.org/education/dietary_guidelines_after_gastric_bypass/. Accessed 17 Dec 2013

13.

Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA (1997) Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 157:2562–2568PubMedCrossRef

14.

Smith SB, Geske JB, Maguire JM, Zane NA, Carter RE, Morgenthaler TI (2010) Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest 137:1382–1390PubMedCentralPubMedCrossRef

15.

Hylek EM, Skates SJ, Sheehan MA, Singer DE (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335:540–546PubMedCrossRef

Title: Rivaroxaban use following bariatric surgery
Authors: Zachariah Thomas
Yaron Bareket
Wendy Bennett
Publication date: 01-07-2014
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 1/2014
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-014-1057-6

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2014

Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies

Preprocedural TIMI flow and infarct size in STEMI undergoing primary angioplasty

Bleeding complications related to warfarin treatment: a descriptive register study from the anticoagulation clinic at Helsingborg Hospital

Hyperhomocysteinemia in patients with pulmonary embolism is associated with impaired plasma fibrinolytic capacity

Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation

A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage